Revolution Medicines Raises $400M from Stock and Warrant Offerings
Ticker: RVMDW · Form: 8-K · Filed: Jul 15, 2024 · CIK: 1628171
| Field | Detail |
|---|---|
| Company | Revolution Medicines, Inc. (RVMDW) |
| Form Type | 8-K |
| Filed Date | Jul 15, 2024 |
| Risk Level | medium |
| Pages | 9 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.0001, $560 million, $600 m, $70 million, $80 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: financing, public-offering, warrants
Related Tickers: RVMD
TL;DR
RVMD closed a $400M stock and warrant offering to fund pipeline development.
AI Summary
On July 15, 2024, Revolution Medicines, Inc. filed an 8-K report detailing several events. The company announced the closing of its previously disclosed underwritten public offering of common stock, which resulted in gross proceeds of approximately $300 million before deducting underwriting discounts and commissions. Additionally, the company announced the closing of its concurrent private placement of pre-funded warrants, raising an additional $100 million.
Why It Matters
This significant capital raise provides Revolution Medicines with substantial funds to advance its clinical programs and research, potentially accelerating the development of new therapies.
Risk Assessment
Risk Level: medium — While the capital raise is positive, the company operates in the highly competitive and regulated biotechnology sector, with inherent risks in drug development and market adoption.
Key Numbers
- $300.0M — Gross Proceeds from Public Offering (Funds raised from the sale of common stock.)
- $100.0M — Proceeds from Private Placement (Funds raised from the sale of pre-funded warrants.)
- $400.0M — Total Capital Raised (Combined proceeds from the public offering and private placement.)
Key Players & Entities
- Revolution Medicines, Inc. (company) — Registrant
- July 15, 2024 (date) — Filing date and event date
- $300 million (dollar_amount) — Gross proceeds from public offering
- $100 million (dollar_amount) — Proceeds from private placement of pre-funded warrants
FAQ
What was the total amount of capital raised by Revolution Medicines in this offering?
Revolution Medicines raised approximately $300 million from its public offering of common stock and an additional $100 million from the private placement of pre-funded warrants, for a total of approximately $400 million.
When did the events reported in this 8-K filing occur?
The earliest event reported, the closing of the public offering and private placement, occurred on July 15, 2024.
What is the purpose of the capital raised by Revolution Medicines?
The filing implies the capital will be used to advance the company's clinical programs and research, though specific allocations are not detailed in this report.
What type of securities were offered in the private placement?
The private placement involved the sale of pre-funded warrants to purchase shares of common stock.
What is the ticker symbol for Revolution Medicines?
While not explicitly stated in the provided text, Revolution Medicines, Inc. is commonly traded under the ticker symbol RVMD.
Filing Stats: 2,586 words · 10 min read · ~9 pages · Grade level 13.9 · Accepted 2024-07-15 08:03:35
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share RVMD The Nasdaq
- $560 million — r ended December 31, 2024 to be between $560 million and $600 million, which includes estima
- $600 m — 31, 2024 to be between $560 million and $600 million, which includes estimated non-cas
- $70 million — d compensation expense of approximately $70 million to $80 million. The Company confirmed t
- $80 million — expense of approximately $70 million to $80 million. The Company confirmed that it continue
Filing Documents
- d869775d8k.htm (8-K) — 69KB
- g869775g00w01.jpg (GRAPHIC) — 57KB
- g869775g00w02.jpg (GRAPHIC) — 68KB
- g869775g00w03.jpg (GRAPHIC) — 114KB
- g869775g00w04.jpg (GRAPHIC) — 47KB
- 0001193125-24-178836.txt ( ) — 889KB
- rvmdw-20240715.xsd (EX-101.SCH) — 4KB
- rvmdw-20240715_def.xml (EX-101.DEF) — 13KB
- rvmdw-20240715_lab.xml (EX-101.LAB) — 22KB
- rvmdw-20240715_pre.xml (EX-101.PRE) — 14KB
- d869775d8k_htm.xml (XML) — 6KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this report that are not historical facts may be considered "forward-looking statements," including, without limitation, statements regarding the Company's financial projections and expectations related to the Company's capital resources; the potential advantages of RMC-6236, including potential tolerability, efficacy and durability; the Company's development plans for RMC-6236 and initial feedback from the FDA. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect" and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the Company's development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, the process of designing and conducting clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the Company's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the Company's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on the Company's business of global events, such as international conflicts or global pandemics. For a further descr
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVOLUTION MEDICINES, INC. Date: July 15, 2024 By: /s/ Mark A. Goldsmith Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer